LLY TUESDAY, OCTOBER 30TH Symposium 5 : Solanezumab Phase 3 results: Implications for Alzheimer's disease modification Eric Siemers, MD, Eli Lilly, USA http://www.ctad.fr/02-program/prog-2012/tuesday.asp#ancre11